FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308136710> ?p ?o ?g. }

• W4308136710 endingPage "e005018" @default.
• W4308136710 startingPage "e005018" @default.
• W4308136710 abstract "Background Indications with poor T-cell infiltration or deficiencies in T-cell priming and associated unresponsiveness to established immunotherapies represent an unmet medical need in oncology. CD40-targeting therapies designed to enhance antigen presentation, generate new tumor-specific T cells, and activate tumor-infiltrating myeloid cells to remodel the tumor microenvironment, represent a promising opportunity to meet this need. In this study, we present the first in vivo data supporting a role for tumor-associated antigen (TAA)-mediated uptake and cross-presentation of tumor antigens to enhance tumor-specific T-cell priming using CD40×TAA bispecific antibodies, a concept we named Neo-X-Prime. Methods Bispecific antibodies targeting CD40 and either of two cell-surface expressed TAA, carcinoembryonic antigen-related cell adhesion molecule 5 (CEA) or epithelial cell adhesion molecule (EpCAM), were developed in a tetravalent format. TAA-conditional CD40 agonism, activation of tumor-infiltrating immune cells, antitumor efficacy and the role of delivery of tumor-derived material such as extracellular vesicles, tumor debris and exosomes by the CD40×TAA bispecific antibodies were demonstrated in vitro using primary human and murine cells and in vivo using human CD40 transgenic mice with different tumor models. Results The results showed that the CD40×TAA bispecific antibodies induced TAA-conditional CD40 activation both in vitro and in vivo. Further, it was demonstrated in vitro that they induced clustering of tumor debris and CD40-expressing cells in a dose-dependent manner and superior T-cell priming when added to dendritic cells (DC), ovalbumin (OVA)-specific T cells and OVA-containing tumor debris or exosomes. The antitumor activity of the Neo-X-Prime bispecific antibodies was demonstrated to be significantly superior to the monospecific CD40 antibody, and the resulting T-cell dependent antitumor immunity was directed to tumor antigens other than the TAA used for targeting (EpCAM). Conclusions The data presented herein support the hypothesis that CD40×TAA bispecific antibodies can engage tumor-derived vesicles containing tumor neoantigens to myeloid cells such as DCs resulting in an improved DC-mediated cross-priming of tumor-specific CD8 + T cells. Thus, this principle may offer therapeutics strategies to enhance tumor-specific T-cell immunity and associated clinical benefit in indications characterized by poor T-cell infiltration or deficiencies in T-cell priming." @default.
• W4308136710 created "2022-11-08" @default.
• W4308136710 creator A5001191544 @default.
• W4308136710 creator A5003121489 @default.
• W4308136710 creator A5003226508 @default.
• W4308136710 creator A5007494633 @default.
• W4308136710 creator A5008420464 @default.
• W4308136710 creator A5012070715 @default.
• W4308136710 creator A5018960981 @default.
• W4308136710 creator A5020569823 @default.
• W4308136710 creator A5025033564 @default.
• W4308136710 creator A5028606030 @default.
• W4308136710 creator A5052107377 @default.
• W4308136710 creator A5052742480 @default.
• W4308136710 creator A5062186545 @default.
• W4308136710 creator A5063849945 @default.
• W4308136710 creator A5065809036 @default.
• W4308136710 creator A5066837870 @default.
• W4308136710 creator A5068228532 @default.
• W4308136710 creator A5070016509 @default.
• W4308136710 creator A5072019967 @default.
• W4308136710 creator A5073829192 @default.
• W4308136710 creator A5043590900 @default.
• W4308136710 date "2022-11-01" @default.
• W4308136710 modified "2023-10-01" @default.
• W4308136710 title "Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies" @default.
• W4308136710 cites W1501518736 @default.
• W4308136710 cites W2046505430 @default.
• W4308136710 cites W2047171958 @default.
• W4308136710 cites W2078592143 @default.
• W4308136710 cites W2096158777 @default.
• W4308136710 cites W2106430203 @default.
• W4308136710 cites W2144796581 @default.
• W4308136710 cites W2155229523 @default.
• W4308136710 cites W2180091996 @default.
• W4308136710 cites W2254172772 @default.
• W4308136710 cites W2261057385 @default.
• W4308136710 cites W2391382367 @default.
• W4308136710 cites W2418018584 @default.
• W4308136710 cites W2503638473 @default.
• W4308136710 cites W2559803603 @default.
• W4308136710 cites W2587048937 @default.
• W4308136710 cites W2888050979 @default.
• W4308136710 cites W2946884236 @default.
• W4308136710 cites W2967833499 @default.
• W4308136710 cites W2971041097 @default.
• W4308136710 cites W2994744934 @default.
• W4308136710 cites W3013673954 @default.
• W4308136710 cites W3134824376 @default.
• W4308136710 cites W3136974297 @default.
• W4308136710 cites W3165190396 @default.
• W4308136710 cites W3211531014 @default.
• W4308136710 cites W4220683566 @default.
• W4308136710 cites W4220864880 @default.
• W4308136710 doi "https://doi.org/10.1136/jitc-2022-005018" @default.
• W4308136710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36323431" @default.
• W4308136710 hasPublicationYear "2022" @default.
• W4308136710 type Work @default.
• W4308136710 citedByCount "3" @default.
• W4308136710 countsByYear W43081367102023 @default.
• W4308136710 crossrefType "journal-article" @default.
• W4308136710 hasAuthorship W4308136710A5001191544 @default.
• W4308136710 hasAuthorship W4308136710A5003121489 @default.
• W4308136710 hasAuthorship W4308136710A5003226508 @default.
• W4308136710 hasAuthorship W4308136710A5007494633 @default.
• W4308136710 hasAuthorship W4308136710A5008420464 @default.
• W4308136710 hasAuthorship W4308136710A5012070715 @default.
• W4308136710 hasAuthorship W4308136710A5018960981 @default.
• W4308136710 hasAuthorship W4308136710A5020569823 @default.
• W4308136710 hasAuthorship W4308136710A5025033564 @default.
• W4308136710 hasAuthorship W4308136710A5028606030 @default.
• W4308136710 hasAuthorship W4308136710A5043590900 @default.
• W4308136710 hasAuthorship W4308136710A5052107377 @default.
• W4308136710 hasAuthorship W4308136710A5052742480 @default.
• W4308136710 hasAuthorship W4308136710A5062186545 @default.
• W4308136710 hasAuthorship W4308136710A5063849945 @default.
• W4308136710 hasAuthorship W4308136710A5065809036 @default.
• W4308136710 hasAuthorship W4308136710A5066837870 @default.
• W4308136710 hasAuthorship W4308136710A5068228532 @default.
• W4308136710 hasAuthorship W4308136710A5070016509 @default.
• W4308136710 hasAuthorship W4308136710A5072019967 @default.
• W4308136710 hasAuthorship W4308136710A5073829192 @default.
• W4308136710 hasBestOaLocation W43081367101 @default.
• W4308136710 hasConcept C100701293 @default.
• W4308136710 hasConcept C147483822 @default.
• W4308136710 hasConcept C154317977 @default.
• W4308136710 hasConcept C159654299 @default.
• W4308136710 hasConcept C185592680 @default.
• W4308136710 hasConcept C202751555 @default.
• W4308136710 hasConcept C203014093 @default.
• W4308136710 hasConcept C2776090121 @default.
• W4308136710 hasConcept C2776107976 @default.
• W4308136710 hasConcept C2776662205 @default.
• W4308136710 hasConcept C2776677690 @default.
• W4308136710 hasConcept C2777701055 @default.
• W4308136710 hasConcept C2778170410 @default.
• W4308136710 hasConcept C39347974 @default.
• W4308136710 hasConcept C502942594 @default.

• next